Biocon partners Adagio for licence to make Covid-19 antibody cocktail

Treatment claims to address the resistant Delta variant as well

Bengaluru-headquartered Biocon Biologics has partnered US-based Adagio Therapeutics for an exclusive licence to manufacture and commercialise an advanced antibody treatment against Covid-19 for India and select markets. 

The antibody treatment is based on ADG20, a novel monoclonal antibody, which targets the spike protein of SARS-CoV-2 and related coronaviruses. It is under clinical development by Adagio as a potential single agent for both the treatment and prevention of Covid-19, a press statement said. 

“Vaccines alone will not protect and make the world safer. Biologic therapies that arrest the virus on its path of devastation are a necessity for sustainable protection and safety,” said